Empresa Stemline Therapeutics, Inc.
Acciones
US85858C1071
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 08/08/03 |
David Gionco
DFI | Director of Finance/CFO | 63 | 16/01/14 |
Jeffrey Levitt
CMP | Compliance Officer | - | 01/03/18 |
Nassir Habboubi
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/21 |
Kenneth Hoberman
COO | Chief Operating Officer | 59 | 01/01/13 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Ivan Bergstein
CEO | Chief Executive Officer | 58 | 08/08/03 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 52 510 785 | 52 125 679 ( 99,27 %) | 0 | 99,27 % |
Información de la empresa
Stemline Therapeutics, Inc.
750 Lexington Avenue 11th floor
10022, New York
+646-502-2310
http://www.stemline.com![Dirección Stemline Therapeutics, Inc.](https://cdn.zonebourse.com/static/address/11168022.png)
Sector
Varia. 1 de ene. | Capi. | |
---|---|---|
+15,20 % | 121 mil M | |
+19,67 % | 113 mil M | |
+18,95 % | 26,02 mil M | |
-23,86 % | 19,39 mil M | |
-19,03 % | 15,91 mil M | |
-20,90 % | 15,09 mil M | |
-46,14 % | 15,06 mil M | |
+63,85 % | 14,93 mil M | |
+4,49 % | 13,85 mil M |